How much is a share of htgm worth?
One share of HTGM stock can currently be purchased for approximately $3.51. How much money does HTG Molecular Diagnostics make? HTG Molecular Diagnostics has a market capitalization of $26.57 million and generates $8.55 million in revenue each year.
Should I buy HTG molecular diagnostics stock?
The consensus among Wall Street analysts is that investors should "buy" HTG Molecular Diagnostics stock. View analyst ratings for HTG Molecular Diagnostics or view top-rated stocks. Are investors shorting HTG Molecular Diagnostics? HTG Molecular Diagnostics saw a increase in short interest in December.
Do htgm and conformis hold clues to what lies ahead?
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022.
What is HTG edgeseq technology?
Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Should I buy HTGM stock?
The financial health and growth prospects of HTGM, demonstrate its potential to underperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
What is the long range forecast for HTGM stock?
Based on our forecasts, a long-term increase is expected, the "HTGM" stock price prognosis for 2027-07-09 is 4.409 USD. With a 5-year investment, the revenue is expected to be around +132.67%. Your current $100 investment may be up to $232.67 in 2027. Get It Now!
Should I buy or sell HTG Molecular Diagnostics stock right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 3...
What is HTG Molecular Diagnostics' stock price forecast for 2022?
3 analysts have issued twelve-month price targets for HTG Molecular Diagnostics' stock. Their forecasts range from $3.00 to $10.00. On average, the...
Are investors shorting HTG Molecular Diagnostics?
HTG Molecular Diagnostics saw a increase in short interest in May. As of May 31st, there was short interest totaling 153,900 shares, an increase of...
When is HTG Molecular Diagnostics' next earnings date?
HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings foreca...
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its earnings results on Tuesday, March, 29th. The medical research company reported ($0.69)...
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the following people: John L. Lubniewski , President, Chief Executive Officer & Director Shau...
What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?
11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Glassdoor.com . Tim (TJ) Johnson has an approval rating of 47% among HTG...
Who are some of HTG Molecular Diagnostics' key competitors?
Some companies that are related to HTG Molecular Diagnostics include Pressure BioSciences (PBIO) , SeqLL (SQL) , Arrayit (ARYC) , DiaSys (DYXC)...
What other stocks do shareholders of HTG Molecular Diagnostics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Phar...
What is HTG in 2021?
When is HTG's earnings call 2021?
TUCSON, Ariz., June 22, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe. HTG has now signed EAP agreements with customers in both the US and Europe and continues to progress toward its planned third qu
What is HTG technology?
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
What is the net loss for the first quarter of 2021?
HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
3.5 Analyst's Opinion
Net loss from operations for the first quarter ended March 31, 2021 was $4.6 million, compared with $5.4 million for the same period in 2020. Net loss per share was $ (0.80) for the quarter ended March 31, 2021 compared with $ (1.27) for the same period in 2020.
Is HTG Molecular Diagnostics a buy right now?
HTG Molecular Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Are investors shorting HTG Molecular Diagnostics?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 3 buy ratings for the stock.
When is HTG Molecular Diagnostics' next earnings date?
HTG Molecular Diagnostics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 72,200 shares, a decline of 38.1% from the December 31st total of 116,700 shares.
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022. View our earnings forecast for HTG Molecular Diagnostics.
What price target have analysts set for HTGM?
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its quarterly earnings data on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60).
What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?
3 brokers have issued 12 month price objectives for HTG Molecular Diagnostics' shares. Their forecasts range from $8.00 to $10.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $9.00 in the next year.
The past three years for HTG Molecular Diagnostics (NASDAQ:HTGM) investors has not been profitable
11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among HTG Molecular Diagnostics' employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?
Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in...
Here is What Hedge Funds Think About HTG Molecular Diagnostics, Inc. (HTGM)
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional.
Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 5) Aclaris Therapeutics, Inc. (NASDAQ: ACRS) Cara Therapeutics, Inc. (NASDAQ: CARA) Gain Therapeutics, Inc. (NASDAQ: GANX) IDEAYA Biosciences, Inc. (NASDAQ: IDYA) Magenta Therapeutics, Inc.
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News & Analysis: HTG Molecular Diagnostics
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a .8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition of Decipher Biosciences, Inc.
Environmental, Social, and Governance Rating
There is no available coverage of HTG Molecular Diagnostics at this time.
